NEC OncoImmunity publishes research using its neoantigen prediction technology showing improved outcome in sarcoma patients treated with cancer immunotherapy

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Software
Research
Pharmaceutical
Oncology
Technology
Artificial Intelligence
Health Technology
Clinical Trials
Science
Biotechnology
Other Science
Health
neoantigen prediction

More Like This

Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

T cells helping immune system to fight cancer cells in response to immunotherapies (Photo: Business Wire)

GE HealthCare Announces New Data Validating Artificial Intelligence Models for Predicting Patient Response to Immunotherapies

PR Newswire associated0

Sengenics Corporation Unveils i-Ome® Cancer: A Breakthrough in Cancer Precision Medicine

ACCESSWIRE associated1

Revolutionizing Drug Development: Novigenix Unveils AI-Powered RNA Analysis for Immune Response Profiling

NEC Laboratories Europe and Data-Driven.AI enhance AI medical diagnosis to improve the early detection of disease and illness

New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented

Professor Nguyen Thanh Liem, Director, Institute of Stem Cell and Genetic Technology Research at Vinmec International Hospital, Hanoi, Vietnam and his team have successfully implemented the technology transfer of Autologous Immune Enhancement Therapy (AIET) from Japan and demonstrated its safety and efficacy as an adjuvant in combination with standard of care in various cancers. Prof. Liem, a renowned pediatric surgeon and pioneer in regenerative medicine, has received numerous prestigious honors, including the 2018 Nikkei Asia Prize for Science & Technology, the Ho Chi Minh Prize, the Hero of Labor Medal, and the Vietnamese Talent Award. In 2025, he was named among the world's most influential scientists by a Stanford University, USA research group. Driven by a passion to improve cancer patients’ quality of life, Prof. Liem successfully brought AIET to Vietnam in 2018 transferred by GN Corporation, Japan, technically supported by Nichi-In Centre for Regenerative Medicine (NCRM)

Colorectal, Liver, and Lung Cancer Patients at Vinmec Experience Extended Survival with AIET Cell-Based Immunotherapy – Technology Transferred from Japan